Pseudoephedrine Use During Pregnancy
Pseudoephedrine should be avoided during pregnancy, particularly in the first trimester, due to concerns about vascular disruption defects including gastroschisis, though the absolute risk remains low. If nasal congestion requires treatment, intranasal saline, intranasal cromolyn, or intranasal corticosteroids (like beclomethasone) are safer first-line alternatives 1, 2.
FDA Labeling and Official Guidance
The FDA drug label explicitly states: "If pregnant or breast-feeding, ask a health professional before use" 1. This cautionary language reflects the lack of definitive safety data and documented concerns about potential fetal effects.
Evidence on Malformation Risk
Most Recent Large-Scale Study (2025)
The highest quality recent evidence comes from a large Israeli population-based cohort of 251,543 pregnancies 3. This study found:
- First-trimester exposure to high-dose pseudoephedrine (120 mg) showed no association with major congenital malformations overall (adjusted RR = 0.90,95% CI 0.558-1.45)
- No increased risk by organ system, including cardiovascular, CNS, musculoskeletal, gastrointestinal, or genitourinary malformations
Contradictory Earlier Evidence
However, earlier case-control studies identified specific concerns that cannot be dismissed:
- Gastroschisis risk increased 4.2-fold with pseudoephedrine-acetaminophen combination (95% CI 1.9-9.2) 4
- Associations with small intestinal atresia and hemifacial microsomia—defects thought to arise from vascular disruption 5
- Risk appears amplified in women who smoke, due to additive vasoconstrictive effects 5
Mechanism of Concern
Pseudoephedrine is an alpha-adrenergic receptor agonist causing vasoconstriction 5. The theoretical concern is that vasoconstriction during critical periods of organogenesis could cause vascular disruption defects by reducing blood flow to developing structures. While one study showed no acute changes in uterine or fetal blood flow after a single 60 mg dose in third trimester 6, this doesn't address chronic first-trimester exposure during organogenesis.
Clinical Decision Algorithm
First trimester (weeks 1-13):
- Avoid pseudoephedrine due to vascular disruption concerns
- Use intranasal saline irrigation first
- If inadequate, use intranasal cromolyn or intranasal beclomethasone 2
- First-generation antihistamines (chlorpheniramine) are safer alternatives for allergic rhinitis 2
Second and third trimesters:
- Risk appears lower, but still recommend avoidance if alternatives available
- If absolutely necessary, use lowest effective dose for shortest duration
- Standard dose is 30-60 mg 1, but avoid exceeding recommended dosing 1
Contraindications regardless of trimester:
- Concurrent MAOI use or within 2 weeks of discontinuation 1
- Maternal hypertension, heart disease, thyroid disease, or diabetes (relative contraindications requiring careful assessment) 1
Critical Caveats
Smoking amplifies risk: Women who smoke should absolutely avoid pseudoephedrine due to synergistic vasoconstrictive effects 5
Recall bias in older studies: The case-control studies showing increased gastroschisis risk 4 may suffer from maternal recall bias, while the recent cohort study 3 used pharmacy records (more reliable)
Combination products: Many over-the-counter products contain pseudoephedrine plus other ingredients—ensure you're assessing the complete formulation
Animal data concerns: A 2024 rat study showed dose-dependent decreased ossification and calcium content in fetal bones 7, though animal findings don't always translate to humans
Practical Recommendation
Given the conflicting evidence, the prudent approach is avoidance, especially since effective alternatives exist. The 2025 cohort study 3 is reassuring but doesn't completely eliminate the earlier signals of vascular disruption defects 5, 4. In real-world practice, the risk-benefit calculation favors safer alternatives unless severe symptoms require treatment and other options have failed.